Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

[1]  E. Herzog,et al.  Comparison of In‐Hospital Mortality and Length of Stay in Acute ST‐Segment‐Elevation Myocardial Infarction Among Urban Teaching Hospitals in China and the United States , 2019, Journal of the American Heart Association.

[2]  Á. Avezum,et al.  Complete Revascularization with Multivessel PCI for Myocardial Infarction. , 2019, The New England journal of medicine.

[3]  P. Song,et al.  Efficacy of postprocedural anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction , 2019, Medicine.

[4]  S. Windecker,et al.  Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. , 2019, Journal of the American College of Cardiology.

[5]  G. Montalescot,et al.  Anticoagulation, the Unknown of the Antithrombotic Equation After Stenting of an Acute Coronary Syndrome. , 2019, Journal of the American College of Cardiology.

[6]  Jeroen J. Bax,et al.  Fourth universal definition of myocardial infarction (2018). , 2018, European heart journal.

[7]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[8]  [2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction]. , 2019, Zhonghua xin xue guan bing za zhi.

[9]  J. Iqbal,et al.  Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study) , 2018, Thrombosis and Haemostasis.

[10]  F. Neumann,et al.  Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials , 2018, Clinical Research in Cardiology.

[11]  G. Helft,et al.  Periprocedural myocardial infarction and injury in elective coronary stenting , 2018, European heart journal.

[12]  H. Ai,et al.  Safety of early discharge after primary angioplasty in low-risk patients with ST-segment elevation myocardial infarction: A meta-analysis of randomised controlled trials , 2018, European journal of preventive cardiology.

[13]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[14]  J. Douketis,et al.  2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. , 2017, The Canadian journal of cardiology.

[15]  G. Stone,et al.  Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials , 2017, European heart journal. Acute cardiovascular care.

[16]  G. Stone,et al.  Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial , 2017, European heart journal. Acute cardiovascular care.

[17]  C. Held,et al.  Bivalirudin versus Heparin Monotherapy in Myocardial Infarction , 2017, The New England journal of medicine.

[18]  S. de Servi,et al.  Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTalian cardiac care units Registry , 2017, Journal of cardiovascular medicine.

[19]  R. Welsh,et al.  Outcomes and Prognostic Impact of Prophylactic Oral Anticoagulation in Anterior ST‐Segment Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction , 2017, Journal of the American Heart Association.

[20]  F. Fernández‐Avilés,et al.  Very low risk ST-segment elevation myocardial infarction? It exists and may be easily identified. , 2017, International journal of cardiology.

[21]  G. Stone,et al.  Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[22]  D. Angiolillo,et al.  Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study. , 2016, Journal of the American College of Cardiology.

[23]  G. Cheng,et al.  Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. , 2016, International journal of cardiology.

[24]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[25]  P. Jüni,et al.  Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[26]  D. Angiolillo,et al.  Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation. , 2015, JACC. Cardiovascular interventions.

[27]  G. Stone,et al.  Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. , 2015, JAMA.

[28]  R. Swaminathan,et al.  Hospital length of stay and clinical outcomes in older STEMI patients after primary PCI: a report from the National Cardiovascular Data Registry. , 2015, Journal of the American College of Cardiology.

[29]  R. Abbate,et al.  Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. , 2015, Journal of the American College of Cardiology.

[30]  J. Shambrook,et al.  Cardiac MR assessment of microvascular obstruction. , 2015, The British journal of radiology.

[31]  G. Wells,et al.  Prophylactic warfarin therapy after primary percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. , 2015, JACC. Cardiovascular interventions.

[32]  Mike Fisher,et al.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial , 2014, The Lancet.

[33]  G. Stone,et al.  Postprocedural anticoagulation for specific therapeutic indications after revascularization for ST-segment elevation myocardial infarction (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial). , 2014, The American journal of cardiology.

[34]  H. Schunkert,et al.  Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. , 2014, European heart journal.

[35]  S. Pocock,et al.  Bivalirudin started during emergency transport for primary PCI. , 2013, The New England journal of medicine.

[36]  H. Gray,et al.  Key recommendations and evidence from the NICE guideline for the acute management of ST-segment-elevation myocardial infarction , 2013, Heart.

[37]  Deepak L. Bhatt,et al.  Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. , 2013, Journal of the American College of Cardiology.

[38]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[39]  T. Akasaka,et al.  Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[40]  S. Plein,et al.  Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial , 2012, The Lancet.

[41]  D. Singer,et al.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[42]  Jason C. Fish,et al.  Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[43]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[44]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[45]  E. Vicaut,et al.  Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial , 2011, The Lancet.

[46]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[47]  E. Topol,et al.  Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). , 2010, JACC. Cardiovascular interventions.

[48]  G. Wells,et al.  Primary Percutaneous Coronary Angioplasty With and Without Eptifibatide in ST-Segment Elevation Myocardial Infarction: A Safety and Efficacy Study of Integrilin-Facilitated Versus Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (ASSIST) , 2009, Circulation. Cardiovascular interventions.

[49]  J. Ottervanger,et al.  Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial , 2008, The Lancet.

[50]  E. Topol,et al.  Facilitated PCI in patients with ST-elevation myocardial infarction. , 2008, The New England journal of medicine.

[51]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[52]  S. Steinhubl,et al.  Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. , 2006, The New England journal of medicine.

[53]  E. Antman,et al.  Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. , 2006, The New England journal of medicine.

[54]  S. Yusuf,et al.  Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. , 2006, JAMA.

[55]  S. Yusuf,et al.  Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. , 2005, JAMA.

[56]  H. White,et al.  The TETAMI Trial: The Safety and Efficacy of Subcutaneous Enoxaparin versus Intravenous Unfractionated Heparin and of Tirofiban versus Placebo in the Treatment of Acute Myocardial Infarction for Patients Not Thrombolyzed: Methods and Design , 2000, Journal of Thrombosis and Thrombolysis.

[57]  H. White,et al.  The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. , 2003, Journal of the American College of Cardiology.

[58]  J. J. Griffin,et al.  Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial , 2003, Circulation.

[59]  H. Arnesen,et al.  Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.

[60]  J. J. Griffin,et al.  Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. , 2002, The New England journal of medicine.

[61]  Assent investigators.  Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction , 2001, The Lancet.

[62]  M. Morice,et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.

[63]  S. Yusuf,et al.  Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis , 2000, The Lancet.

[64]  M. Whooley,et al.  Adding Heparin to Aspirin Reduces the Incidence of Myocardial Infarction and Death in Patients With Unstable Angina: A Meta-analysis , 1996 .

[65]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.